Skip to main content

Life Sciences is now live. See how →

Patent Examiner Sun Jae Yoo

Art Unit 1621 · Heterocyclic Drug Compounds & Pharmaceutical Compositions · Tech Center 1600 · 413 applications filed 2021–2026

⚑ Hard · harder than 76% of examiners● Free examiner data

Sun Jae Yoo is a USPTO patent examiner in Art Unit 1621 (Heterocyclic Drug Compounds & Pharmaceutical Compositions) with 413 applications from filing years 2021–2026. Examiner Yoo's allowance rate is 66.9%, below the 82.2% USPTO average for applications filed in the same years. The examiner ranks harder than 76% of examiners. In 2021, decided applications with an examiner interview were allowed 37.2 percentage points more often than those without.

Data through November 2026 from USPTO Patent Center (formerly PAIR) · Methodology

Overview

Free
Difficulty · Hard
harder than 76% of examiners
Easier76th percentileHarder
Allowance rate vs peers
Examiner Yoo66.9%
Art Unit 162168.4%
USPTO average82.2%
Allowance rate
66.9%
▼ USPTO avg 82.2%
Applications
413
filing years 2021–2026
First-action allowance
22.6%
patented with no rejection
Abandoned
19.1%
share of applications
Avg office actions
0.8
USPTO avg 1.3
Days to first OA
818
▲ USPTO 615
RCE rate
9.9%
USPTO 18.1%
Interview rate
20.1%
USPTO 26.0%

Examiner details

  • Art unit1621 · Heterocyclic Drug Compounds & Pharmaceutical Compositions
  • Title / gradePrimary Patent Examiner · GS-14
  • Service20 years
  • PhoneOn each office action
  • In USPTO recordsYOO, SUN JAE
Full signatory authority

Examiner Yoo can allow an application without a supervisory sign-off.

Examines (USPC classes)
514 · Drug, Bio-Affecting & Body Treating Compositions546 · Organic Compounds (Class 532-570 Series)544 · Organic Compounds (Class 532-570 Series)

How to improve your odds with Examiner Yoo

  • The data favors an interview. Interviewed cases were allowed more often in all 4 measured years, by 5.0 to 40.0 points.
  • Plan for the timeline. First office action averages 818 days vs the 615-day USPTO norm.
  • Expect a §112. Definiteness & disclosure is the most-issued rejection (77), and applicants overcame it 80.0% of the time.
  • The data favors an RCE here. Cases with an RCE were allowed more often in both measured years, by 28.3 to 42.6 points.

Historical patterns from this examiner's past cases, shown for general information. This is not legal advice and does not predict the outcome of any specific application. Decisions about interviews, RCEs, and claim strategy should be made with a licensed patent attorney or agent.

Rejection patterns & how they get overcome

Free
§102 Novelty76 issued · 64.0% overcome
§112 Definiteness & disclosure77 issued · 80.0% overcome
How applicants traverse §112 rejections🔒 Members

Of the 21 winning responses to Examiner Yoo's §112 rejections that Boundly has classified, 13 (62%) amended without arguing, and 8 amended the claims and argued. Each winning response, with its arguments and claim amendments, is in the file wrapper.

Read the winning §112 argumentsFull REMARKS, amendments, claim trees & redlines from the file wrappers
Start free

Just got an office action from Examiner Yoo?

Draft your response with Examiner Yoo's record and Art Unit 1621's history in view, including the rejection patterns, the interview record, and the arguments that have overcome them. See office action responses in AI Studio.

Open AI Studio free →

RCE behavior

Allowance after a Request for Continued Examination versus without one, per year. Use it to judge whether an RCE is worth the cost in front of Examiner Yoo.

YearRCE rateAllowance w/ RCEAllowance w/oDelta
202215.9%100.0%57.4%+42.6pp
202115.5%92.3%64.0%+28.3pp

Recent outcomes

Free🔒 Case detail for members
App #TitleOutcomeOAsArguments & redline
18/024010Use of PCSK9 Inhibitor in Preparation of Product for Treating Multiple DiseasesPatented1🔒 View
18/343326KRAS G12C InhibitorsPatented0🔒 View
17/9095892,5- or 2,6-Disubstituted Hydroquinone Derivatives with at Least One Carboxy, Sulfo or Amido Group Useful as MedicamentsPatented2🔒 View
18/794040Acrylate Derivative, Use and Production Intermediate Compound of the SamePatented0🔒 View
See all 413 applications with full file-wrapper detailOffice action text, attorney arguments, amendments & claim-by-claim track changes
Start free

Art Unit 1621 technology

Pyrimidines & other diazinesPyridines & piperidinesKinase & enzyme inhibitorsMethods of treatmentTop CPC C07D · A61K · C07C
About this examiner. Sun Jae Yoo examines in Art Unit 1621 (Heterocyclic Drug Compounds & Pharmaceutical Compositions, Tech Center 1600). Working on compound or antibody claims? See Life Sciences in AI Studio.

Frequently asked questions

What is Examiner Sun Jae Yoo's allowance rate?
Examiner Yoo's allowance rate is 66.9%, compared with 82.2% across the USPTO and 68.4% in Art Unit 1621 for applications filed in the same years. That rate ranks Examiner Yoo harder than 76% of examiners.
Is Examiner Yoo a hard examiner?
Somewhat. Examiner Yoo ranks harder than 76% of examiners, in the 76th difficulty percentile (hard). Examiner Yoo has a 66.9% allowance rate versus 82.2% across the USPTO and 68.4% in Art Unit 1621, 0.8 office actions per application versus 1.3, and an RCE rate of 9.9% versus 18.1% across the USPTO, for applications filed in the same years.
Do examiner interviews help with Examiner Yoo?
In this examiner's record, yes. Decided applications with an interview were allowed more often in each of the 4 measured years, by 5.0 to 40.0 percentage points. In 2021, 93.5% of decided applications with an interview were allowed, versus 56.3% of those without.
What is Examiner Yoo's most common rejection?
§112 definiteness & disclosure, issued 77 times in the data. Applicants overcame it 80.0% of the time. Of the 21 winning responses Boundly has classified, 13 amended without arguing.
Is an RCE worth filing with Examiner Yoo?
In this examiner's record, yes. Decided applications with an RCE were allowed more often in both measured years, by 28.3 to 42.6 percentage points. In 2021, 92.3% of decided applications with an RCE were allowed, versus 64.0% of those without one.
How long until the first office action from Examiner Yoo?
About 818 days on average, versus 615 days across the USPTO for applications filed in the same years.

Put Examiner Yoo's data to work on your next response.

Full file-wrapper detail, winning arguments, and AI-assisted drafting in one workspace.

Start free
Statistics are computed by Boundly Prosecution Intel from USPTO Patent Center (formerly PAIR) file wrappers for filing years 2021–2026, refreshed regularly. Allowance rate (sometimes called grant rate) is the share of disposed applications that issued as patents. Office actions here are non-final and final rejections, so restriction requirements and allowances are not counted. USPTO benchmarks are weighted to each examiner's mix of filing years, and art-unit benchmarks to the art units and filing years of the examiner's own applications, so they compare like for like. The difficulty percentile ranks examiners, each counted once, so it can point the other way from the USPTO average, which counts applications. See how each number is computed. The year-by-year interview and RCE tables show up to four recent filing years, leaving out the newest one and any year with fewer than ten applications or five decided applications on either side. Historical data is provided for informational purposes only. Past examiner behavior does not guarantee future outcomes, and nothing here is legal advice or a substitute for advice from a licensed patent attorney or agent. Are you Sun Jae Yoo, or see an error? Request a correction.